Yumi Nakayama1, C Colin Brinkman, Jonathan S Bromberg. 1. 1 Center for Vascular and Inflammatory Diseases, University of Maryland, Baltimore, MD. 2 Departments of Surgery, University of Maryland, Baltimore, MD. 3 Microbiology and Immunology, University of Maryland, Baltimore, MD.
Abstract
BACKGROUND: Costimulatory blockade with anti-CD40L monoclonal antibody (mAb) plus donor-specific splenocyte transfusion (DST) induces alloantigen-specific tolerance. We previously showed that lymphotoxin signaling in the fibroblastic reticular cell (FRC) stromal subset was required for proper lymph node structure and function during tolerization in murine cardiac transplantation. Here we focused on FRC functions and hypothesized that DST and anti-CD40L mAb-modulated FRC interactions with CD4(+) T cells in mice. METHODS: Mice were immunized or tolerized by DST or DST plus anti-CD40L mAb. Fibroblastic reticular cells were flow-sorted at different timepoints for characterization and in vitro proliferation and activation assays. RESULTS: Fibroblastic reticular cells responded rapidly to DST by transcribing inflammatory cytokine and chemokine messenger RNAs, such as CXCL2, CXCL9, CXCL10, and CCL21. Conversely, anti-CD40L mAb inhibited FRC inflammatory responses. CD40 was expressed on FRC and agonistic anti-CD40 mAb activated FRC, which supported CD4(+) T-cell proliferation, whereas unstimulated FRC did not. Anti-CD3 mAb-activated CD4(+) T cells induced inflammatory cytokine and chemokine expressions by FRC, which were inhibited by anti-CD40L mAb. Thus, FRC phenotype was altered by interaction with CD4(+) T cells through CD40-CD40L, and activated FRC interacted directly with CD4(+) T cells to support T cell activation and proliferation in vitro. CONCLUSIONS: Taken together, these results demonstrated that CD40 on FRC facilitated bidirectional communication between FRC and CD4(+) T cells via CD40-CD40L, thereby altering FRC gene expression of immune regulatory molecules. Because blockade of CD40-CD40L interactions results in tolerance in mice, identification of FRC-T cell interactions provides a new research target for tolerance induction.
BACKGROUND: Costimulatory blockade with anti-CD40L monoclonal antibody (mAb) plus donor-specific splenocyte transfusion (DST) induces alloantigen-specific tolerance. We previously showed that lymphotoxin signaling in the fibroblastic reticular cell (FRC) stromal subset was required for proper lymph node structure and function during tolerization in murine cardiac transplantation. Here we focused on FRC functions and hypothesized that DST and anti-CD40L mAb-modulated FRC interactions with CD4(+) T cells in mice. METHODS:Mice were immunized or tolerized by DST or DST plus anti-CD40L mAb. Fibroblastic reticular cells were flow-sorted at different timepoints for characterization and in vitro proliferation and activation assays. RESULTS: Fibroblastic reticular cells responded rapidly to DST by transcribing inflammatory cytokine and chemokine messenger RNAs, such as CXCL2, CXCL9, CXCL10, and CCL21. Conversely, anti-CD40L mAb inhibited FRC inflammatory responses. CD40 was expressed on FRC and agonistic anti-CD40 mAb activated FRC, which supported CD4(+) T-cell proliferation, whereas unstimulated FRC did not. Anti-CD3 mAb-activated CD4(+) T cells induced inflammatory cytokine and chemokine expressions by FRC, which were inhibited by anti-CD40L mAb. Thus, FRC phenotype was altered by interaction with CD4(+) T cells through CD40-CD40L, and activated FRC interacted directly with CD4(+) T cells to support T cell activation and proliferation in vitro. CONCLUSIONS: Taken together, these results demonstrated that CD40 on FRC facilitated bidirectional communication between FRC and CD4(+) T cells via CD40-CD40L, thereby altering FRC gene expression of immune regulatory molecules. Because blockade of CD40-CD40L interactions results in tolerance in mice, identification of FRC-T cell interactions provides a new research target for tolerance induction.
Authors: Benjamin J Marsland; Patrick Bättig; Monika Bauer; Christiane Ruedl; Ute Lässing; Roger R Beerli; Klaus Dietmeier; Lidia Ivanova; Thomas Pfister; Lorenz Vogt; Hideki Nakano; Chiara Nembrini; Philippe Saudan; Manfred Kopf; Martin F Bachmann Journal: Immunity Date: 2005-04 Impact factor: 31.745
Authors: Scott N Mueller; Mehrdad Matloubian; Daniel M Clemens; Arlene H Sharpe; Gordon J Freeman; Shivaprakash Gangappa; Christian P Larsen; Rafi Ahmed Journal: Proc Natl Acad Sci U S A Date: 2007-09-18 Impact factor: 11.205
Authors: Alexander Link; Tobias K Vogt; Stéphanie Favre; Mirjam R Britschgi; Hans Acha-Orbea; Boris Hinz; Jason G Cyster; Sanjiv A Luther Journal: Nat Immunol Date: 2007-09-23 Impact factor: 25.606
Authors: Anne L Fletcher; Deepali Malhotra; Sophie E Acton; Veronika Lukacs-Kornek; Angelique Bellemare-Pelletier; Mark Curry; Myriam Armant; Shannon J Turley Journal: Front Immunol Date: 2011-09-12 Impact factor: 7.561
Authors: Xiaofei Li; Jing Zhao; Vivek Kasinath; Mayuko Uehara; Liwei Jiang; Naima Banouni; Martina M McGrath; Takaharu Ichimura; Paolo Fiorina; Dario R Lemos; Su Ryon Shin; Carl F Ware; Jonathan S Bromberg; Reza Abdi Journal: J Clin Invest Date: 2020-08-03 Impact factor: 14.808
Authors: Jonathan S Bromberg; Lauren Hittle; Yanbao Xiong; Vikas Saxena; Eoghan M Smyth; Lushen Li; Tianshu Zhang; Chelsea Wagner; W Florian Fricke; Thomas Simon; Colin C Brinkman; Emmanuel F Mongodin Journal: JCI Insight Date: 2018-10-04
Authors: Girdhari Lal; Neeraja Kulkarni; Yumi Nakayama; Amit K Singh; Apoorva Sethi; Bryna E Burrell; C Colin Brinkman; Daiki Iwami; Tianshu Zhang; Thomas Hehlgans; Jonathan S Bromberg Journal: Immunol Lett Date: 2016-01-06 Impact factor: 3.685
Authors: Thomas Simon; Lushen Li; Chelsea Wagner; Tianshu Zhang; Vikas Saxena; C Colin Brinkman; Lisa H Tostanoski; Suzanne Ostrand-Rosenberg; Chris Jewell; Terez Shea-Donohue; Keli Hippen; Bruce Blazar; Reza Abdi; Jonathan S Bromberg Journal: Transplantation Date: 2019-10 Impact factor: 4.939